METHODS FOR PREDICTING DRUG RESPONSIVENESS IN CANCER PATIENTS

1 . A method of predicting the responsiveness to treatment in a patient having diffuse large B-cell lymphoma comprising:

(a) determining a level of expression of one or more first biomarkers selected from the group consisting of hsa-miR-766_st and hsa-miR-34b_st in a biological sample from said patient, wherein said treatment is selected from the group consisting of:

i) cyclophosphamide, vincristine, and etoposide (COPE);

ii) methotrexate, carmustine, and teniposide (MBVP);

iii) dexamethasone, ara-c, and cisplatin (DHAP);

iv) ifosfamide, carboplatin, and etoposide (ICE);

v) etoposide, ifosfamide, and methotrexate (VIM);

vi) methyl-GAG, ifosfamide, methotrexate, and etoposide (MIME);

vii) etoposide, cytarabine, and cisplatin (ESHAP);

viii) cyclophosphamide, carmustine, and etoposide (CBV);

ix) cyclophosphamide, etoposide, vincristine, and doxorubicine (EPOCH);

x) fludarabine, cyclophosphamide, and mitoxantrone (FCM);

xi) cyclophosphamide, vincristine, doxorubicin, and dexamethasone (CVAD-A);

xii) methotrexate and cytarabine (CVAD-B);

xiii) ifosfamide, mitoxantrone, and etoposide (MINE);

xiv) mechlorethamine, vincristine, and procarbazine (MOPP);

xv) cyclophosphamide, vincristine, adriamycine, and etoposide (CHOEP);

xvi) cyclophosphamide, vincristine, adriamycine, and belinostat (BeICHOP);

xvii) methotrexate (MTX);

xviii) doxorubicin; and

xix) bendamustine; or

(b) determining the level of hsa-miR-766_st in a biological sample from said patient, wherein said treatment is selected from the group consisting of:

i) adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD);

ii) cyclophosphamide, vincristine, adriamycine (CHOP); and

iii) prednisolone; or

(c) determining the level of hsa-miR-34b_st in a biological sample from said patient, wherein said treatment is gemcitabine and oxaliplatin (GemOx);

wherein said level of expression of hsa-miR-766_st and/or hsa-miR-34b_st indicates whether said patient is responsive to said treatment.

2 .- 20 . (canceled)

21 . The method of claim 1 , wherein said method further comprises determining the level of expression of one or more second biomarkers in said biological sample from said patient or in a second biological sample from said patient, wherein the level of expression of said one or more second biomarkers indicates said patient is responsive to said treatment, wherein said treatment is selected from the group consisting of:

i) COPE and said one or more second biomarkers is selected from the group consisting of ACA48_x_st, ENSG00000202498_x_st, HBII-85-26_x_st, HBII-85-6_x_st, hsa-miR-106b-star_st, hsa-miR-1181_st, hsa-miR-124_st, hsa-miR-1281_st, hsa-miR-1299_st, hsa-miR-140-3p_st, hsa-miR-195-star_st, hsa-miR-25-star_st, hsa-miR-33b-star_st, hsa-miR-409-3p_st, hsa-miR-432_st, hsa-miR-551b-star_st, hsa-miR-631_st, hsa-miR-671-5p_st, and hsa-miR-93-star_st; and

ii) MBVP and said one or more second biomarkers is selected from the group consisting of ACA10_s_st, ACA11_st, ACA13_st, ACA18_x_st, ACA21_st, ACA40_x_st, ACA41_x_st, ACA48_st, ACA48_x_st, ACA51_x_st, ACA57_st, ACA61_st, ACA7_s_st, ACA9_st, ENSG00000199411_s_st, ENSG00000200879_st, ENSG00000200932_st, ENSG00000201859_x_st, ENSG00000202252_st, ENSG00000207002_st, ENSG00000207002_x_st, HBII-115_st, HBII-135_x_st, HBII-180A_x_st, HBII-180C_x_st, HBII-202_st, HBII-239_st, HBII-336_st, HBII-429_st, HBII-55_st, HBII-85-26_st, HBII-85-6_x_st, U104_st, U13_st, U17a_st, U17a_x_st, U17b_st, U17b_x_st, U22_st, U25_st, U27_st, U29_st, U3-2_s_st, U30_st, U31_x_st, U32A_x_st, U33_st, U34_st, U38A_st, U38B_st, U41_st, U48_st, U49A_st, U49A_x_st, U49B_s_st, U52_st, U55_st, U55_x_st, U56_st, U56_x_st, U57_st, U64_st, U67_st, U67_x_st, U68_st, U68_x_st, U71a_st, U71b_x_st, U71d_st, U71d_x_st, U74_x_st, U78_s_st, U78_x_st, U83B_st, U89_st, U8_x_st, U95_st, hsa-miR-106a_st, hsa-miR-106b-star_st, hsa-miR-1183_st, hsa-miR-1246_st, hsa-miR-124_st, hsa-miR-1254_st, hsa-miR-1275_st, hsa-miR-1281_st, hsa-miR-1299_st, hsa-miR-140-3p_st, hsa-miR-142-3p_st, hsa-miR-142-5p_st, hsa-miR-153_st, hsa-miR-17-star_st, hsa-miR-17_st, hsa-miR-181a-star_st, hsa-miR-18a-star_st, hsa-miR-18a_st, hsa-miR-195-star_st, hsa-miR-19a_st, hsa-miR-19b_st, hsa-miR-20a_st, hsa-miR-223_st, hsa-miR-25-star_st, hsa-miR-297_st, hsa-miR-33b-star_st, hsa-miR-423-3p_st, hsa-miR-423-5p_st, hsa-miR-491-3p_st, hsa-miR-595_st, hsa-miR-631_st, hsa-miR-663b_st, hsa-miR-671-5p_st, hsa-miR-768-3p_st, hsa-miR-768-5p_st, hsa-miR-769-5p_st, hsa-miR-874_st, hsa-miR-877-star_st, hsa-miR-92a-1-star_st, hsa-miR-92a_st, and hsa-miR-93-star_st; and

iii) DHAP and said one or more second biomarkers is selected from the group consisting of ACA7_s_st, ENSG00000199282_st, ENSG00000200879_st, ENSG00000201299_x_st, ENSG00000201859_x_st, ENSG00000202252_st, ENSG00000202498_x_st, HBII-202_st, HBII-336_st, HBII-429_st, HBII-438A_s_st, HBII-55_st, HBII-85-11_st, HBII-85-26_st, HBII-85-29_x_st, HBII-85-2_x_st, HBII-85-6_x_st, U104_st, U13_st, U17a_st, U17a_x_st, U17b_st, U17b_x_st, U3-2 s_st, U30_st, U33_st, U41_st, U48_st, U49A_st, U49A_x_st, U49B_s_st, U52_st, U55_st, U55_x_st, U57_st, U67_st, U71b_x_st, U78_s_st, U83_st, hsa-miR-106b-star_st, hsa-miR-1183_st, hsa-miR-1207-5p_st, hsa-miR-1268_st, hsa-miR-1281_st, hsa-miR-140-3p_st, hsa-miR-150_st, hsa-miR-155_st, hsa-miR-181a-star_st, hsa-miR-181a_st, hsa-miR-181b_st, hsa-miR-181c_st, hsa-miR-195-star_st, hsa-miR-198_st, hsa-miR-20b-star_st, hsa-miR-223_st, hsa-miR-297_st, hsa-miR-33b-star_st, hsa-miR-342-3p_st, hsa-miR-342-5p_st, hsa-miR-424-star_st, hsa-miR-432_st, hsa-miR-503_st, hsa-miR-574-5p_st, hsa-miR-613_st, hsa-miR-615-3p_st, hsa-miR-631_st, hsa-miR-768-5p_st, hsa-miR-877-star_st, hsa-miR-92a-2-star_st, and hsa-miR-938_st; and

iv) ICE and said one or more second biomarkers is selected from the group consisting of 14qII-14_st, 14qII-1_st, 14qII-26_st, ACA48_x_st, ENSG00000199282_st, ENSG00000201859_x_st, ENSG00000202498_x_st, HBII-85-26_st, HBII-85-6_x_st, U52_st, U55_st, U55_x_st, U8_x_st, hsa-miR-106b-star_st, hsa-miR-124_st, hsa-miR-127-3p_st, hsa-miR-1281_st, hsa-miR-1299_st, hsa-miR-140-3p_st, hsa-miR-181a-star_st, hsa-miR-181a_st, hsa-miR-181b_st, hsa-miR-181c_st, hsa-miR-181d_st, hsa-miR-195-star_st, hsa-miR-199b-3p_st, hsa-miR-297_st, hsa-miR-299-3p_st, hsa-miR-342-3p_st, hsa-miR-342-5p_st, hsa-miR-377-star_st, hsa-miR-409-3p_st, hsa-miR-409-5p_st, hsa-miR-410_st, hsa-miR-432_st, hsa-miR-487b_st, hsa-miR-615-3p_st, hsa-miR-631_st, hsa-miR-654-3p_st, hsa-miR-671-5p_st, hsa-miR-92b_st, hsa-miR-93-star_st, and hsa-miR-938_st; and

v) VIM and said one or more second biomarkers is selected from the group consisting of ACA10_s_st, ACA11_st, ACA13_st, ACA18_x_st, ACA21_st, ACA48_st, ACA48_x_st, ACA7_s_st, ENSG00000199411_s_st, ENSG00000200879_st, ENSG00000200932_st, ENSG00000201859_x_st, ENSG00000202252_st, ENSG00000202498_x_st, ENSG00000207002_st, HBII-115_st, HBII-180A_x_st, HBII-202_st, HBII-336_st, HBII-429_st, HBII-55_st, HBII-85-26_st, HBII-85-6_x_st, U104_st, U13_st, U17a_st, U17b_st, U17b_x_st, U25_st, U27_st, U29_st, U3-2_s_st, U30_st, U31_x_st, U32A_x_st, U33_st, U34_st, U38A_st, U41_st, U48_st, U49A_st, U49A_x_st, U49B_s_st, U52_st, U55_st, U55_x_st, U56_st, U56_x_st, U57_st, U64_st, U67_st, U67_x_st, U68_st, U68_x_st, U71b_x_st, U71d_x_st, U74_x_st, U83B_st, U8_x_st, hsa-miR-106a_st, hsa-miR-106b-star_st, hsa-miR-1246_st, hsa-miR-124_st, hsa-miR-1254_st, hsa-miR-1275_st, hsa-miR-1281_st, hsa-miR-1307_st, hsa-miR-153_st, hsa-miR-17-star_st, hsa-miR-17_st, hsa-miR-181a-star_st, hsa-miR-18a-star_st, hsa-miR-18a_st, hsa-miR-195-star_st, hsa-miR-19a_st, hsa-miR-19b_st, hsa-miR-223_st, hsa-miR-25-star_st, hsa-miR-297_st, hsa-miR-33b-star_st, hsa-miR-423-3p_st, hsa-miR-423-5p_st, hsa-miR-663b_st, hsa-miR-768-3p_st, hsa-miR-768-5p_st, hsa-miR-769-5p_st, hsa-miR-92a-1-star_st, hsa-miR-92a_st, and hsa-miR-93-star_st; and

vi) MIME and said one or more second biomarkers is selected from the group consisting of ACA10_s_st, ACA11_st, ACA13_st, ACA18_x_st, ACA21_st, ACA40_x_st, ACA48_x_st, ACA51_x_st, ACA55_st, ACA61_st, ACA7_s_st, ACA9_st, ENSG00000199282_st, ENSG00000199411_s_st, ENSG00000200879_st, ENSG00000202252_st, ENSG00000202498_x_st, ENSG00000207002_st, ENSG00000207002_x_st, HBII-180A_x_st, HBII-180C_x_st, HBII-202_st, HBII-239_st, HBII-336_st, HBII-429_st, HBII-55_st, HBII-85-26_st, HBII-85-6_x_st, HBII-85-8_x_st, U104_st, U13_st, U17a_st, U17a_x_st, U17b_st, U17b_x_st, U22_st, U25_st, U26_st, U27_st, U28_st, U29_st, U3-2_s_st, U30_st, U31_x_st, U33_st, U34_st, U36A_st, U38A_st, U41_st, U43_x_st, U48_st, U49A_st, U49A_x_st, U49B_s_st, U52_st, U55_st, U55_x_st, U56_st, U56_x_st, U57_st, U59B_st, U64_st, U67_st, U68_st, U71a_st, U71b_x_st, U71d_x_st, U74_x_st, U75_st, U78_s_st, U78_x_st, U83B_st, U83_st, hsa-miR-106a_st, hsa-miR-106b-star_st, hsa-miR-1183_st, hsa-miR-1246_st, hsa-miR-124_st, hsa-miR-1254_st, hsa-miR-1275_st, hsa-miR-1281_st, hsa-miR-1307_st, hsa-miR-153_st, hsa-miR-17-star_st, hsa-miR-17_st, hsa-miR-181a-star_st, hsa-miR-181b_st, hsa-miR-18a-star_st, hsa-miR-18a_st, hsa-miR-18b_st, hsa-miR-195-star_st, hsa-miR-19a_st, hsa-miR-19b_st, hsa-miR-20a_st, hsa-miR-223_st, hsa-miR-25-star_st, hsa-miR-297_st, hsa-miR-33b-star_st, hsa-miR-423-3p_st, hsa-miR-423-5p_st, hsa-miR-425-star_st, hsa-miR-595_st, hsa-miR-615-3p_st, hsa-miR-663b_st, hsa-miR-768-3p_st, hsa-miR-768-5p_st, hsa-miR-769-5p_st, hsa-miR-92a-1-star_st, hsa-miR-92a_st, and hsa-miR-93-star_st; and

vii) ESHAP and said one or more second biomarkers is selected from the group consisting of ACA48_x_st, ACA7_s_st, ENSG00000201859_x_st, HBII-202_st, HBII-429_st, HBII-438A_s_st, HBII-55_st, HBII-85-11_st, HBII-85-26_st, HBII-85-2_x_st, HBII-85-6_x_st, HBII-85-8_x_st, U104_st, U17b_st, U17b_x_st, U33_st, U48_st, U52_st, U55_st, U55_x_st, U57_st, U67_st, U74_x_st, U78_s_st, U78_x_st, U95_st, hsa-miR-124_st, hsa-miR-1281_st, hsa-miR-140-3p_st, hsa-miR-181a-star_st, hsa-miR-181a_st, hsa-miR-181b_st, hsa-miR-181c_st, hsa-miR-195-star_st, hsa-miR-223_st, hsa-miR-297_st, hsa-miR-342-3p_st, hsa-miR-342-5p_st, hsa-miR-424-star_st, and hsa-miR-768-5p_st; and

viii) CBV and said one or more second biomarkers is selected from the group consisting of ACA48_x_st, ACA7_s_st, ENSG00000199282_st, ENSG00000202252_st, ENSG00000202498_x_st, ENSG00000207002_st, HBII-202_st, HBII-85-26_st, HBII-85-6_x_st, U104_st, U17a_st, U34_st, U41_st, U52_st, U55_st, U55_x_st, U57_st, U67_st, U74_x_st, hsa-miR-106a-star_st, hsa-miR-106b-star_st, hsa-miR-1181_st, hsa-miR-1183_st, hsa-miR-1228_st, hsa-miR-124_st, hsa-miR-1281_st, hsa-miR-1299_st, hsa-miR-140-3p_st, hsa-miR-181a-star_st, hsa-miR-181a_st, hsa-miR-181b_st, hsa-miR-181c_st, hsa-miR-195-star_st, hsa-miR-223_st, hsa-miR-297_st, hsa-miR-339-5p_st, hsa-miR-342-3p_st, hsa-miR-342-5p_st, hsa-miR-432_st, hsa-miR-551b-star_st, hsa-miR-610_st, hsa-miR-615-3p_st, hsa-miR-631_st, hsa-miR-671-5p_st, hsa-miR-768-3p_st, hsa-miR-768-5p_st, hsa-miR-769-5p_st, hsa-miR-92b_st, hsa-miR-93-star_st, and hsa-miR-938_st; and

ix) EPOCH and said one or more second biomarkers is selected from the group consisting of ACA48_x_st, ENSG00000202498_x_st, HBII-85-26_st, HBII-85-6_x_st, U55_st, U55_x_st, hsa-miR-106b-star_st, hsa-miR-106b_st, hsa-miR-1181_st, hsa-miR-124_st, hsa-miR-127-3p_st, hsa-miR-1281_st, hsa-miR-1299_st, hsa-miR-140-3p_st, hsa-miR-195-star_st, hsa-miR-25-star_st, hsa-miR-33b-star_st, hsa-miR-409-3p_st, hsa-miR-432_st, hsa-miR-551 b-star_st, hsa-miR-629-star_st, hsa-miR-652_st, hsa-miR-654-3p_st, hsa-miR-671-5p_st, hsa-miR-877-star_st, hsa-miR-92b_st, hsa-miR-93-star_st, and hsa-miR-93_st; and

x) FCM and said one or more second biomarkers is selected from the group consisting of ACA7_s_st, HBII-438A_s_st, HBII-85-11_st, HBII-85-2_x_st, HBII-85-6_x_st, U104_st, U52_st, hsa-miR-1281_st, hsa-miR-1299_st, hsa-miR-140-3p_st, hsa-miR-155_st, hsa-miR-181a-2-star_st, hsa-miR-181a-star_st, hsa-miR-181a_st, hsa-miR-181b_st, hsa-miR-181c_st, hsa-miR-181d_st, hsa-miR-223_st, hsa-miR-342-3p_st, hsa-miR-342-5p_st, hsa-miR-34c-3p_st, hsa-miR-424-star_st, hsa-miR-489_st, hsa-miR-503_st, hsa-miR-768-5p_st, hsa-miR-874_st, and hsa-miR-92b_st; and

xi) CVAD-A and said one or more second biomarkers is selected from any one or more of ENSG00000201125_x_st, ENSG00000201859_x_st, ENSG00000202498_x_st, HBII-85-26_st, HBII-85-6_x_st, U17b_st, U17b_x_st, U48_st, U49A_st, U49A_x_st, U49B_s_st, U55_st, U55_x_st, hsa-miR-106a-star_st, hsa-miR-106b-star_st, hsa-miR-1183_st, hsa-miR-1207-5p_st, hsa-miR-1271_st, hsa-miR-1281_st, hsa-miR-128_st, hsa-miR-150_st, hsa-miR-181c-star_st, hsa-miR-195-star_st, hsa-miR-20b-star_st, hsa-miR-223_st, hsa-miR-297_st, hsa-miR-324-3p_st, hsa-miR-33b-star_st, hsa-miR-342-3p_st, hsa-miR-342-5p_st, hsa-miR-361-5p_st, hsa-miR-424-star_st, hsa-miR-424_st, hsa-miR-432_st, hsa-miR-503_st, hsa-miR-631_st, hsa-miR-671-5p_st, hsa-miR-769-5p_st, and hsa-miR-92a-2-star_st; and

xii) CVAD-B and said one or more second biomarkers is selected from the group consisting of ACA21_st, ACA48_st, ACA48_x_st, ENSG00000200879_st, HBII-202_st, HBII-336_st, HBII-429_st, HBII-438A_s_st, HBII-55_st, U104_st, U17a_x_st, U17b_st, U17b_x_st, U25_st, U27_st, U29_st, U30_st, U31_x_st, U32A_x_st, U33_st, U34_st, U48_st, U49A_st, U49A_x_st, U49B_s_st, U55_st, U55_x_st, U56_st, U56_x_st, U57_st, U67_st, U74_x_st, U78_s_st, U78_x_st, hsa-miR-153_st, hsa-miR-17_st, hsa-miR-181a-star_st, hsa-miR-18a-star_st, hsa-miR-18a_st, hsa-miR-223_st, hsa-miR-25-star_st, hsa-miR-297_st, hsa-miR-33b-star_st, hsa-miR-663b_st, hsa-miR-768-5p_st, and hsa-miR-92a_st; and

xiii) MINE and said one or more second biomarkers is selected from the group consisting of 14qII-14_st, 14qII-14_x_st, 14qII-1_st, 14qII-26_st, 14qII-26_x_st, ENSG00000202498_x_st, HBII-85-26_st, HBII-85-6_x_st, U104_st, U52_st, U55_st, U55_x_st, hsa-miR-124_st, hsa-miR-127-3p_st, hsa-miR-1281_st, hsa-miR-1299_st, hsa-miR-140-3p_st, hsa-miR-181a-star_st, hsa-miR-181a_st, hsa-miR-181b_st, hsa-miR-181c-star_st, hsa-miR-181c_st, hsa-miR-181d_st, hsa-miR-195-star_st, hsa-miR-297_st, hsa-miR-299-3p_st, hsa-miR-29b-2-star_st, hsa-miR-339-5p_st, hsa-miR-33b-star_st, hsa-miR-342-3p_st, hsa-miR-342-5p_st, hsa-miR-377-star_st, hsa-miR-379_st, hsa-miR-381_st, hsa-miR-409-3p_st, hsa-miR-409-5p_st, hsa-miR-411_st, hsa-miR-432_st, hsa-miR-433_st, hsa-miR-487b_st, hsa-miR-493_st, hsa-miR-654-3p_st, hsa-miR-671-5p_st, hsa-miR-768-3p_st, hsa-miR-768-5p_st, hsa-miR-92b_st, and hsa-miR-938_st; and

xiv) MOPP and said one or more second biomarkers is selected from the group consisting of ACA13_st, ACA21_st, ACA48_x_st, ENSG00000199282_st, ENSG00000201299_x_st, HBII-239_st, HBII-336_st, HBII-85-26_st, HBII-85-2_x_st, HBII-85-6_x_st, U104_st, U13_st, U22_st, U55_st, U55_x_st, U74_x_st, U8_x_st, hsa-miR-124_st, hsa-miR-1281_st, hsa-miR-1299_st, hsa-miR-140-3p_st, hsa-miR-181a-star_st, hsa-miR-181a_st, hsa-miR-181b_st, hsa-miR-181c_st, hsa-miR-195-star_st, hsa-miR-297_st, hsa-miR-29b-2-star_st, hsa-miR-331-5p_st, hsa-miR-33b-star_st, hsa-miR-342-3p_st, hsa-miR-342-5p_st, hsa-miR-424-star_st, hsa-miR-432_st, hsa-miR-489_st, hsa-miR-768-3p_st, hsa-miR-768-5p_st, hsa-miR-874_st, hsa-miR-877-star_st, and hsa-miR-92b_st; and

xv) CHOEP and said one or more second biomarkers is selected from the group consisting of ACA48_x_st, ENSG00000202498_x_st, HBII-85-26_st, HBII-85-6_x_st, U55_st, U55_x_st, hsa-miR-106b-star_st, hsa-miR-106b_st, hsa-miR-1181_st, hsa-miR-124_st, hsa-miR-127-3p_st, hsa-miR-1281_st, hsa-miR-1299_st, hsa-miR-140-3p_st, hsa-miR-195-star_st, hsa-miR-25-star_st, hsa-miR-33b-star_st, hsa-miR-409-3p_st, hsa-miR-432_st, hsa-miR-551b-star_st, hsa-miR-629-star_st, hsa-miR-652_st, hsa-miR-654-3p_st, hsa-miR-671-5p_st, hsa-miR-877-star_st, hsa-miR-92b_st, hsa-miR-93-star_st, and hsa-miR-93_st and

xvi) BeICHOP and said one or more second biomarkers is selected from the group consisting of ACA10_s_st, ACA13_st, ACA18_x_st, ACA48_x_st, ACA9_st, ENSG00000200932_st, HBII-180A_x_st, HBII-55_st, HBII-85-26_st, HBII-85-6_x_st, U104_st, U13_st, U17a_st, U17b_st, U17b_x_st, U22_st, U38A_st, U49B_s_st, U51_st, U55_st, U55_x_st, U56_st, U56_x_st, U57_st, U67_st, U71a_st, hsa-miR-106a_st, hsa-miR-106b-star_st, hsa-miR-106b_st, hsa-miR-1181_st, hsa-miR-1228_st, hsa-miR-1246_st, hsa-miR-124_st, hsa-miR-1254_st, hsa-miR-1268_st, hsa-miR-1281_st, hsa-miR-1299_st, hsa-miR-17-star_st, hsa-miR-181c-star_st, hsa-miR-18a-star_st, hsa-miR-18a_st, hsa-miR-18b_st, hsa-miR-195-star_st, hsa-miR-19a_st, hsa-miR-19b_st, hsa-miR-25-star_st, hsa-miR-25_st, hsa-miR-297_st, hsa-miR-33b-star_st, hsa-miR-346_st, hsa-miR-551b-star_st, hsa-miR-593-star_st, hsa-miR-595_st, hsa-miR-611_st, hsa-miR-629-star_st, hsa-miR-629_st, hsa-miR-631_st, hsa-miR-652_st, hsa-miR-671-5p_st, hsa-miR-769-5p_st, hsa-miR-877-star_st, hsa-miR-93-star_st, and hsa-miR-93_st; and

xvii) MTX and said one or more second biomarkers is selected from the group consisting of ACA10_s_st, ACA18_x_st, ACA48_x_st, ACA51_x_st, ENSG00000199411_s_st, ENSG00000200879_st, HBII-180A_x_st, HBII-180C_x_st, HBII-202_st, HBII-429_st, HBII-55_st, U104_st, U17a_st, U17b_st, U17b_x_st, U25_st, U26_st, U27_st, U29_st, U3-2_s_st, U30_st, U31_x_st, U33_st, U38A_st, U48_st, U49A_st, U49A_x_st, U49B_s_st, U49B_x_st, U55_st, U55_x_st, U56_st, U56_x_st, U57_st, U67_st, U67_x_st, U74_x_st, U78_x_st, U89_st, hsa-miR-106a_st, hsa-miR-1246_st, hsa-miR-1254_st, hsa-miR-1275_st, hsa-miR-17-star_st, hsa-miR-17_st, hsa-miR-18a-star_st, hsa-miR-18a_st, hsa-miR-18b_st, hsa-miR-19a_st, hsa-miR-19b_st, hsa-miR-20a_st, hsa-miR-25-star_st, hsa-miR-297_st, hsa-miR-33b-star_st, hsa-miR-663b_st, hsa-miR-768-5p_st, hsa-miR-92a-1-star_st, hsa-miR-92a_st, and hsa-miR-936_st; and

xviii) doxorubicin and said one or more second biomarkers is selected from the group consisting of ACA13_st, ACA48_x_st, U104_st, U55_st, U55_x_st, U74_x_st, hsa-miR-106a-star_st, hsa-miR-106b-star_st, hsa-miR-106b_st, hsa-miR-124_st, hsa-miR-1281_st, hsa-miR-1299_st, hsa-miR-140-3p_st, hsa-miR-195-star_st, hsa-miR-297_st, hsa-miR-29b-2-star_st, hsa-miR-33b-star_st, hsa-miR-342-3p_st, hsa-miR-342-5p_st, hsa-miR-432_st, hsa-miR-550-star_st, hsa-miR-629-star_st, hsa-miR-629_st, hsa-miR-652_st, hsa-miR-654-3p_st, hsa-miR-671-5p_st, hsa-miR-768-3p_st, hsa-miR-877-star_st, hsa-miR-93-star_st, and hsa-miR-93_st; and

xix) bendamustine and said one or more second biomarkers is selected from the group consisting of ACA11_st, ACA24_x_st, ACA7_s_st, HBII-115_st, HBII-438A_s_st, HBII-85-11_st, U13_st, U49B_s_st, hsa-miR-106b-star_st, hsa-miR-128_st, hsa-miR-1299_st, hsa-miR-142-5p_st, hsa-miR-153_st, hsa-miR-155_st, hsa-miR-15a-star_st, hsa-miR-15a_st, hsa-miR-181a-star_st, hsa-miR-181a_st, hsa-miR-181b_st, hsa-miR-181c_st, hsa-miR-20b-star_st, hsa-miR-29b-2-star_st, hsa-miR-29c-star_st, hsa-miR-29c_st, hsa-miR-342-5p_st, hsa-miR-361-5p_st, hsa-miR-363-star_st, hsa-miR-647_st, and hsa-miR-93-star_st.

22 .- 52 . (canceled)

53 . The method of claim 1 , further comprising administering said treatment to said patient, wherein said determining occurs: i) prior to said administration; ii) substantially concurrent with said administration; or iii) after said administration.

54 .- 56 . (canceled)

57 . The method of claim 53 , wherein said determining step occurs multiple times.

58 .- 61 . (canceled)

62 . The method of claim 1 , further comprising, prior to said determining, providing said biological sample obtained from said patient, wherein said biological sample is selected from formalin-fixed paraffin embedded (FFPE) tissue or fresh frozen tissue.

63 .- 64 . (canceled)

65 . The method of claim 62 , wherein said biological sample is obtained from a tumor, and wherein said biological sample comprises a tumor biopsy.

66 . (canceled)

67 . The method of claim 65 , wherein said biological sample comprises a tumor biopsy from a patient having suffered a relapse of diffuse large B-cell lymphoma after a first, second, or third line therapy.

68 .- 124 . (canceled)

125 . The method of claim 21 , wherein the level of expression of at least one, at least two, at least three, at least four, at least five, or each of said second biomarkers is determined in said patient.

126 .- 130 . (canceled)

131 . The method of claim 21 , further comprising administering one or more additional therapies to said patient, wherein said one or more additional therapies is administered: i) concurrently with administration of said treatment, ii) prior to administration of said treatment, or iii) after administration of said treatment.

132 .- 135 . (canceled)

136 . The method of claim 131 , wherein said one or more additional therapies comprises one or more additional therapeutic agents, surgery, or radiation therapy.

137 . The method of claim 136 , wherein said one or more additional therapeutic agents is selected from the group consisting of cyclophosphamide, vincristine, and etoposide (COPE); methotrexate, carmustine, and teniposide (MBVP); dexamethasone, ara-c, and cisplatin (DHAP); ifosfamide, carboplatin, and etoposide (ICE); etoposide, ifosfamide, and methotrexate (VIM); methyl-GAG, ifosfamide, methotrexate, and etoposide (MIME); etoposide, cytarabine, methylprednisolone, and cisplatin (ESHAP); cyclophosphamide, carmustine, and etoposide (CBV); cyclophosphamide, etoposide, vincristine, and doxorubicine (EPOCH); fludarabine, cyclophosphamide, and mitoxantrone (FCM); cyclophosphamide, vincristine, doxorubicin, and dexamethasone (CVAD-A); methotrexate and cytarabine (CVAD-B); ifosfamide, mitoxantrone, and etoposide (MINE); mechlorethamine, vincristine, and procarbazine (MOPP); cyclophosphamide, vincristine, adriamycine, and etoposide (CHOEP); cyclophosphamide, vincristine, adriamycine, and belinostat (BeICHOP); methotrexate (MTX); doxorubicin; bendamustine; adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD); cyclophosphamide, vincristine, adriamycine (CHOP); prednisolone; and gemcitabine and oxaliplatin (GemOx).

138 . The method of claim 21 , wherein said treatment is administered to said patient intravenously, orally, intraperitoneally, intramuscularly, topically, rectally, cutaneously, subcutaneously, nasally, intracerebroventricularly, intraparenchymally, intrathecally, intracranially, ocularly, via inhalation, or through the skin.

139 . (canceled)

140 . The method of claim 21 , further comprising administering said treatment two or more times.

141 .- 148 . (canceled)

149 . The method of claim 21 , wherein said treatment is administered in dosage form.

150 . The method of claim 1 , wherein said patient is a human.

151 .- 152 . (canceled)

153 . The method of claim 1 , wherein said patient has suffered a relapse of diffuse large B-cell lymphoma.

154 . The method of claim 1 , wherein said level of expression of said first biomarkers is determined by detecting the level of microRNA in the biological sample.

155 . The method of claim 1 , wherein said method further comprises, prior to said determining, amplifying hsa-miR-766_st and/or hsa-miR-34b_st nucleic acid molecules in said biological sample or reverse transcribing hsa-miR-766_st and/or hsa-miR-34b in said biological sample, further wherein the product of said amplification or said reverse transcription is cDNA.

156 .- 158 . (canceled)

159 . The method of claim 1 , wherein said level of expression of said first biomarkers is determined using sequencing.

160 . (canceled)

161 . The method of claim 21 , wherein said level of expression of said first biomarkers or said second biomarkers is determined using a microarray, wherein said microarray comprises a plurality of nucleic acid probes, and wherein each of said nucleic acid probes has a length of about 5 nucleotides.

162 . The method of claim 161 , wherein each of said nucleic acid probes are configured to hybridize to a target RNA molecule or a target cDNA molecule.

163 . (canceled)

164 . The method of claim 162 or 163 , wherein the nucleic acid sequence of said target RNA molecule or said target cDNA molecule is identical or complementary to all or a portion of the nucleic acid sequence of at least one of said first biomarkers or said second biomarkers.

165 .- 166 . (canceled)

167 . The method of claim 1 , wherein said level of expression of hsa-miR-766_st is determined using a probe capable of hybridizing to a nucleic acid molecule having the sequence of SEQ ID NO. 246, wherein said probe comprises a nucleic acid sequence comprising at least 15 continuous nucleotides and at least 85% sequence identity to a sequence complementary to SEQ ID NO. 246.

168 . (canceled)

169 . The method of claim 1 , wherein said level of expression of hsa-miR-34b_st is determined using a probe capable of hybridizing to a nucleic acid molecule having the sequence of SEQ ID NO. 185, wherein said probe comprises a nucleic acid sequence comprising at least 15 continuous nucleotides and at least 85% sequence identity to a sequence complementary to SEQ ID NO. 185.

170 . (canceled)

171 . The method of claim 21 , further comprising determining the level of expression of one or more of said second biomarkers in a biological sample from said patient, wherein said level of expression of said second biomarkers is determined using a probe capable of hybridizing to a nucleic acid molecule comprising the nucleic acid sequence of said second biomarkers, wherein said second biomarkers are selected from one or more of the biomarkers of Table 1, and wherein said probe comprises a sequence comprising at least 15 continuous nucleotides and at least 85% sequence identity to a sequence complementary to any one of SEQ ID NOs. 1-263.

172 .- 174 . (canceled)

175 . The method of claim 1 , further comprising converting said level of expression of one or more of said first biomarkers into a mean score for said treatment, wherein said mean score identifies the responsiveness of said patient to said treatment.

176 . (canceled)

177 . The method of claim 1 , wherein the patient is predicted to be responsive to said treatment if the level of expression of said first biomarkers is statistically different from the level of expression of said first biomarkers in a control.

178 . The method of claim 177 , wherein:

(a) if the level of expression of said first biomarkers indicates that the patient is responsive to said treatment, said method further comprises administering said treatment to the patient as a first cancer treatment; or

(b) if the level of expression of said first biomarkers indicates that the patient is non-responsive to said treatment, said method further comprises administering a second cancer treatment that is different from the first cancer treatment.

179 . The method of claim 21 , wherein the patient is predicted to be responsive to said treatment if the level of expression of one or more of said second biomarkers is statistically different from the level of expression of one or more of said second biomarkers in a control.

180 . The method of claim 179 , wherein:

(a) if the level of expression of said second biomarker indicates that the patient is responsive to said treatment, said method further comprises administering said treatment to the patient as a first cancer treatment; or

(b) if the level of expression of second biomarker indicates that the patient is non-responsive to said treatment, said method further comprises administering a second cancer treatment that is different from the first cancer treatment.

181 . A method of treating a patient having diffuse large B-cell lymphoma, said method comprising:

(a) administering a first cancer treatment to the patient, wherein the patient was previously determined to be responsive to the first cancer treatment according to the method of claim 1 ; or

(b) administering a second cancer treatment that is different from the first cancer treatment to the patient, wherein the patient was previously determined to be non-responsive to the first cancer treatment according to the method of claim 1 , wherein the first cancer treatment is selected from the group consisting of:

i) cyclophosphamide, vincristine, and etoposide (COPE);

ii) methotrexate, carmustine, and teniposide (MBVP);

iii) dexamethasone, ara-c, and cisplatin (DHAP);

iv) ifosfamide, carboplatin, and etoposide (ICE);

v) etoposide, ifosfamide, and methotrexate (VIM);

vi) methyl-GAG, ifosfamide, methotrexate, and etoposide (MIME);

vii) etoposide, cytarabine, and cisplatin (ESHAP);

viii) cyclophosphamide, carmustine, and etoposide (CBV);

ix) cyclophosphamide, etoposide, vincristine, and doxorubicine (EPOCH);

x) fludarabine, cyclophosphamide, and mitoxantrone (FCM);

xi) cyclophosphamide, vincristine, doxorubicin, and dexamethasone (CVAD-A);

xii) methotrexate and cytarabine (CVAD-B);

xiii) ifosfamide, mitoxantrone, and etoposide (MINE);

xiv) mechlorethamine, vincristine, and procarbazine (MOPP);

xv) cyclophosphamide, vincristine, adriamycine, and etoposide (CHOEP);

xvi) cyclophosphamide, vincristine, adriamycine, and belinostat (BeICHOP);

xvii) methotrexate (MTX);

xviii) doxorubicin;

xix) bendamustine;

xx) adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD);

xxi) cyclophosphamide, vincristine, adriamycine (CHOP); and

xxii) prednisolone; and

xxiii) gemcitabine and oxaliplatin (GemOx).

182 . The method of claim 181 , wherein the patient in (b) is administered both the first cancer treatment and the second cancer treatment.